Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients

NCT04492254 is registered in ClinicalTrials.gov with Thrombosis Research Institute as lead sponsor.

NCT NCT04492254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04492254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients
Lead sponsor
Thrombosis Research Institute
Phase
Phase 3
Overall status
Terminated
Start date
October 27, 2020
Completion date
November 29, 2021
Enrollment
219 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19